Same evidence, varying viewpoints: Three questions illustrating important differences between United States and European cholesterol guideline recommendations
In 2018, the AHA/ACC Multisociety Guideline on the Management of Blood Cholesterol was released. Less than one year later, the 2019 ESC/EAS Dyslipidemia Guideline was published. While both provide important recommendations for managing atherosclerotic cardiovascular disease (ASCVD) risk through lipi...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-12-01
|
Series: | American Journal of Preventive Cardiology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666667720301173 |
id |
doaj-920cfbf6bfce41818820348d5f71d15c |
---|---|
record_format |
Article |
spelling |
doaj-920cfbf6bfce41818820348d5f71d15c2021-03-19T07:32:53ZengElsevierAmerican Journal of Preventive Cardiology2666-66772020-12-014100117Same evidence, varying viewpoints: Three questions illustrating important differences between United States and European cholesterol guideline recommendationsDavid I. Feldman0Erin D. Michos1Neil J. Stone2Ty J. Gluckman3Miguel Cainzos-Achirica4Salim S. Virani5Roger S. Blumenthal6The Ciccarone Center for the Prevention of Cardiovascular Disease, The Johns Hopkins University School of Medicine, Baltimore, MD, USAThe Ciccarone Center for the Prevention of Cardiovascular Disease, The Johns Hopkins University School of Medicine, Baltimore, MD, USADepartments of Medicine (Cardiology) and Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USACenter for Cardiovascular Analytics, Research and Data Science (CARDS), Providence Heart Institute, Providence St. Joseph Health, Portland, OR, USA; The Ciccarone Center for the Prevention of Cardiovascular Disease, The Johns Hopkins University School of Medicine, Baltimore, MD, USADivision of Cardiovascular Prevention and Wellness, Department of Cardiology, Houston Methodist Hospital, Houston, TX, USA; The Ciccarone Center for the Prevention of Cardiovascular Disease, The Johns Hopkins University School of Medicine, Baltimore, MD, USAHealth Policy, Quality and Informatics Program, Michael E. DeBakey Veterans Affairs Medical Center Health Services Research and Development Center for Innovations; And Section of Cardiovascular Research, Baylor College of Medicine, Houston, TX, USAThe Ciccarone Center for the Prevention of Cardiovascular Disease, The Johns Hopkins University School of Medicine, Baltimore, MD, USA; Corresponding author. Halsted 560, Ciccarone Center for the Prevention of Cardiovascular Disease, 600 N. Wolfe Street, Baltimore, MD, 21287, USA.In 2018, the AHA/ACC Multisociety Guideline on the Management of Blood Cholesterol was released. Less than one year later, the 2019 ESC/EAS Dyslipidemia Guideline was published. While both provide important recommendations for managing atherosclerotic cardiovascular disease (ASCVD) risk through lipid management, differences exist. Prior to the publication of both guidelines, important randomized clinical trial data emerged on non-statin lipid lowering therapy and ASCVD risk reduction. To illustrate important differences in guideline recommendations, we use this data to help answer three key questions: 1) Are ASCVD event rates similar in high-risk primary and stable secondary prevention? 2) Does imaging evidence of subclinical atherosclerosis justify aggressive use of statin and non-statin therapy (if needed) to reduce LDL-C levels below 55 mg/dL as recommended in the European Guideline? 3) Do LDL-C levels below 70 mg/dL achieve a large absolute risk reduction in secondary ASCVD prevention? The US guideline prioritizes both the added efficacy and cost implications of non-statin therapy, which limits intensive therapy to individuals with the highest risk of ASCVD. The European approach broadens the eligibility criteria by incorporating goals of therapy in both primary and secondary prevention. The current cost and access constraints of healthcare worldwide, especially amidst a COVID-19 pandemic, makes the European recommendations more challenging to implement. By restricting non-statin therapy to a subgroup of high- and, in particular, very high-risk individuals, the US guideline provides primary and secondary ASCVD prevention recommendations that are more affordable and attainable. Ultimately, finding a common ground for both guidelines rests on our ability to design trials that assess cost-effectiveness in addition to efficacy and safety.http://www.sciencedirect.com/science/article/pii/S2666667720301173ASCVD Risk assessmentASCVD PreventionLipid-lowering therapy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
David I. Feldman Erin D. Michos Neil J. Stone Ty J. Gluckman Miguel Cainzos-Achirica Salim S. Virani Roger S. Blumenthal |
spellingShingle |
David I. Feldman Erin D. Michos Neil J. Stone Ty J. Gluckman Miguel Cainzos-Achirica Salim S. Virani Roger S. Blumenthal Same evidence, varying viewpoints: Three questions illustrating important differences between United States and European cholesterol guideline recommendations American Journal of Preventive Cardiology ASCVD Risk assessment ASCVD Prevention Lipid-lowering therapy |
author_facet |
David I. Feldman Erin D. Michos Neil J. Stone Ty J. Gluckman Miguel Cainzos-Achirica Salim S. Virani Roger S. Blumenthal |
author_sort |
David I. Feldman |
title |
Same evidence, varying viewpoints: Three questions illustrating important differences between United States and European cholesterol guideline recommendations |
title_short |
Same evidence, varying viewpoints: Three questions illustrating important differences between United States and European cholesterol guideline recommendations |
title_full |
Same evidence, varying viewpoints: Three questions illustrating important differences between United States and European cholesterol guideline recommendations |
title_fullStr |
Same evidence, varying viewpoints: Three questions illustrating important differences between United States and European cholesterol guideline recommendations |
title_full_unstemmed |
Same evidence, varying viewpoints: Three questions illustrating important differences between United States and European cholesterol guideline recommendations |
title_sort |
same evidence, varying viewpoints: three questions illustrating important differences between united states and european cholesterol guideline recommendations |
publisher |
Elsevier |
series |
American Journal of Preventive Cardiology |
issn |
2666-6677 |
publishDate |
2020-12-01 |
description |
In 2018, the AHA/ACC Multisociety Guideline on the Management of Blood Cholesterol was released. Less than one year later, the 2019 ESC/EAS Dyslipidemia Guideline was published. While both provide important recommendations for managing atherosclerotic cardiovascular disease (ASCVD) risk through lipid management, differences exist. Prior to the publication of both guidelines, important randomized clinical trial data emerged on non-statin lipid lowering therapy and ASCVD risk reduction. To illustrate important differences in guideline recommendations, we use this data to help answer three key questions: 1) Are ASCVD event rates similar in high-risk primary and stable secondary prevention? 2) Does imaging evidence of subclinical atherosclerosis justify aggressive use of statin and non-statin therapy (if needed) to reduce LDL-C levels below 55 mg/dL as recommended in the European Guideline? 3) Do LDL-C levels below 70 mg/dL achieve a large absolute risk reduction in secondary ASCVD prevention? The US guideline prioritizes both the added efficacy and cost implications of non-statin therapy, which limits intensive therapy to individuals with the highest risk of ASCVD. The European approach broadens the eligibility criteria by incorporating goals of therapy in both primary and secondary prevention. The current cost and access constraints of healthcare worldwide, especially amidst a COVID-19 pandemic, makes the European recommendations more challenging to implement. By restricting non-statin therapy to a subgroup of high- and, in particular, very high-risk individuals, the US guideline provides primary and secondary ASCVD prevention recommendations that are more affordable and attainable. Ultimately, finding a common ground for both guidelines rests on our ability to design trials that assess cost-effectiveness in addition to efficacy and safety. |
topic |
ASCVD Risk assessment ASCVD Prevention Lipid-lowering therapy |
url |
http://www.sciencedirect.com/science/article/pii/S2666667720301173 |
work_keys_str_mv |
AT davidifeldman sameevidencevaryingviewpointsthreequestionsillustratingimportantdifferencesbetweenunitedstatesandeuropeancholesterolguidelinerecommendations AT erindmichos sameevidencevaryingviewpointsthreequestionsillustratingimportantdifferencesbetweenunitedstatesandeuropeancholesterolguidelinerecommendations AT neiljstone sameevidencevaryingviewpointsthreequestionsillustratingimportantdifferencesbetweenunitedstatesandeuropeancholesterolguidelinerecommendations AT tyjgluckman sameevidencevaryingviewpointsthreequestionsillustratingimportantdifferencesbetweenunitedstatesandeuropeancholesterolguidelinerecommendations AT miguelcainzosachirica sameevidencevaryingviewpointsthreequestionsillustratingimportantdifferencesbetweenunitedstatesandeuropeancholesterolguidelinerecommendations AT salimsvirani sameevidencevaryingviewpointsthreequestionsillustratingimportantdifferencesbetweenunitedstatesandeuropeancholesterolguidelinerecommendations AT rogersblumenthal sameevidencevaryingviewpointsthreequestionsillustratingimportantdifferencesbetweenunitedstatesandeuropeancholesterolguidelinerecommendations |
_version_ |
1724213220962467840 |